http://matome.naver.jp/odai/2137055426917829901レミマゾラム (remimazolam)
Simulations based on these models show that remimazolam delivers extremely rapid sedation, with maximal effect being reached within 3 minutes of the start of treatment. This property will enable maintenance doses to be given more accurately than with slower-acting drugs.
出典
Anesth Analg. 2012 Aug;115(2):284-96.
Remimazolam provided sedation with rapid onset and offset, and was well tolerated. There was no supplemental oxygen or ventilation required. On the basis of these data, further studies on the potential utility of remimazolam for sedation/anesthesia are warranted.
出典
Anesth Analg. 2012 Aug;115(2):274-83.
Remimazolam (CNS-7056) appears to have potential advantages over other currently available short-acting sedatives.
出典
IDrugs. 2010 Dec;13(12):929-37.
CNS 7056 has PK-PD properties compatible with its potential human use as a short-acting i.v. sedative.
出典
Br J Anaesth. 2010 Dec;105(6):798-809.
CNS 7056 is a powerful and short-acting anaesthetic in sheep with respiratory and cardiovascular effects consistent with its sedative/anaesthetic qualities.
出典
Br J Anaesth. 2009 Dec;103(6):848-57.
Doses of 0.37-2.21 mg kg(-1) of CNS 7056 produced sedation for 9-25 min without excessive respiratory or cardiovascular depression, and would be suitable for pharmacokinetic studies. The power in the alpha band of the EEG can be used as a continuous measure of the sedative effects of CNS 7056.
出典
Br J Pharmacol. 2008 September; 155(1): 52–61.
CNS 7065 is a high-affinity and selective ligand for the benzodiazepine site on the GABAA receptor. CNS 7056 does not show selectivity between GABAA receptor subtypes. CNS 7056 is a potent sedative in rodents with a short duration of action. Inhibition of substantia nigra pars reticulata firing and the inhibition of the effects of CNS 7056 by flumazenil show that it acts at the brain benzodiazepine receptor.
出典
Anesthesiology. 2007 Jul;107(1):60-6
http://www.youtube.com/watch?v=uhRkTj8OY6s